Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President and Representative 
Director: Masayuki Kobayashi) announced on August 29 that the company has 
entered into an agreement to invest up to US$30 million in Remiges BioPharma 
Fund II, LP a biopharma venture capital fund formed by Remiges Ventures, Inc. 
Taiho Pharmaceutical invested the same amount in the Remiges BioPharma Fund I 
established in 2014.

(Logo: https://kyodonewsprwire.jp/img/201908239964-O1-AZU8HYZr)

Taiho Pharmaceutical has made use of the Remiges BioPharma Fund I as a platform 
for open innovation with academia, research institutions, and startups in the 
early stages of development in the US and Europe. Going forward, the company 
will establish and strengthen its network with venture businesses that have 
early seeds in the US, Europe, Israel, Japan, and elsewhere, in an effort to 
enhance its new drug development capabilities by actively accessing innovative 
technologies. Taiho Pharmaceutical will also dispatch employees to Remiges 
Ventures in an ongoing effort to develop human resources who are capable of 
making good assessments from a global perspective. 

By investing in promising new external technologies, in addition to the 
in-house drug discovery infrastructure that it has developed over many years, 
Taiho Pharmaceutical hopes to increase its portfolio of innovative drugs that 
can make a positive contribution to the world. 

Overview of Remiges BioPharma Fund II, LP
-Fund name: Remiges BioPharma Fund II, LP
-Established: June 2019
-Operating bases: Tokyo, Japan, and Boston and Seattle, USA
-Fund size: Up to US$150 million
-Fund term: 10 years
-Investment areas: Seed/early stage pharmaceuticals and medical devices
-Investment regions: North America, Europe, Israel, Japan, and elsewhere
-URL: www.remigesventures.com

About Taiho Pharmaceutical Co., Ltd. (Japan)
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an 
R&D-driven specialty pharma company with a focus on oncology. Taiho 
Pharmaceutical also has development programs in allergy and immunology, urology 
and consumer healthcare products. Its corporate philosophy is simple: "We 
strive to improve human health and contribute to a society enriched by smiles." 

For more information about Taiho Pharmaceutical, please visit: 
https://www.taiho.co.jp/en/.


SOURCE: Taiho Pharmaceutical Co., Ltd.